Security Snapshot

Indivior Pharmaceuticals, Inc. - Common stock, $0.001 par value per share (the "Common Stock") (INDV) Institutional Ownership

CUSIP: G4766E116

13F Institutional Holders and Ownership History from Q2 2023 to Q2 2026

13F reference period

Q2 2026

Institutions Reporting

0

Shares (Excl. Options)

0

Price

$32.97

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common stock, $0.001 par value per share (the "Common Stock")
Symbol
INDV on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
0
Latest holder snapshot 4 signals
Total 13F value
$0
Share change
-214,389
Value change
-$6,535,613
Number of holders
0
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
123,290,343
SEC-reported price per share
$32.97
Insider filing price
$32.97
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • INDV - Indivior Pharmaceuticals, Inc. - Common stock, $0.001 par value per share (the "Common Stock") is tracked under CUSIP G4766E116.
  • 0 institutions reported positions in Q2 2026.
  • 11 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 3 to 0 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $6.54MFull value: $6,535,613 · USD · 31 Mar 2026
    to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 0 institutions filings for Q2 2026.

Open SEC evidence

Security key

G4766E116

13F reference period

Q2 2026

13F holders

0

13D/G owners

11

CIK / CUSIP context first

Open Q2 2026 holders INDV full holder history Indivior Pharmaceuticals, Inc. SEC filings Indivior Pharmaceuticals, Inc. company facts Indivior Pharmaceuticals, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
11
Security
INDV
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 14% +107% $638,884,065 +$335,082,637 17,806,183 +110% BlackRock, Inc. 31 Dec 2025
VANGUARD PORTFOLIO MANAGEMENT LLC 6.6% $272,463,211 7,994,836 Vanguard Portfolio Management 31 Mar 2026
Oaktree Capital Holdings, LLC 5.7% -19% $232,808,746 -$53,592,755 7,108,664 -19% Oaktree Capital Holdings, LLC 24 Dec 2025
VANGUARD CAPITAL MANAGEMENT LLC 5.4% $222,327,725 6,523,720 Vanguard Capital Management 31 Mar 2026
Two Seas Capital LP 5% -12% $203,438,218 -$27,837,500 6,211,854 -12% Two Seas Capital LP 23 Dec 2025
MILLENNIUM MANAGEMENT LLC 3.8% +90% $158,472,151 +$77,320,782 4,806,556 +95% Millennium Management LLC 17 Mar 2026
MORGAN STANLEY 3.7% $53,976,433 4,665,206 Morgan Stanley 31 Mar 2025
Flynn James E 3.7% -60% $111,255,547 -$143,518,681 4,614,498 -56% Deerfield Mgmt, L.P. 10 Nov 2025
FULLER & THALER ASSET MANAGEMENT, INC. 3.7% -28% $146,214,501 -$59,457,962 4,529,583 -29% Fuller & Thaler Asset Management, Inc. 31 Mar 2026
Madison Avenue Partners, LP 3.5% -30% $139,292,998 -$63,440,979 4,315,162 -31% Madison Avenue International LP 31 Mar 2026
GOLDMAN SACHS GROUP INC 2.9% -46% $122,142,647 -$99,940,892 3,592,431 -45% THE GOLDMAN SACHS GROUP, INC. 31 Dec 2025
As of 30 Jun 2026, 0 institutional investors reported holding 0 shares of Indivior Pharmaceuticals, Inc. - Common stock, $0.001 par value per share (the "Common Stock") (INDV). This represents 0% of the company’s total
123.29MFull value: 123,290,343 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
13
Headline period
Q2 2026
Rows shown
1-13 of 13
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 0 $0 -$6,535,613 $32.97 0
2026 Q1 214,389 $6,535,613 -$3,852,702,409 $30.48 3
2025 Q4 113,035,472 $4,053,440,634 -$18,859,469 $35.88 247
2025 Q3 110,811,392 $2,670,071,230 +$380,369,121 $24.11 196
2025 Q2 106,959,206 $1,577,697,144 +$260,685,760 $14.74 119
2025 Q1 91,341,313 $865,955,709 +$119,981,356 $9.53 115
2024 Q4 77,790,536 $974,764,447 +$68,457,241 $12.43 112
2024 Q3 71,540,427 $699,253,141 +$54,237,351 $9.75 100
2024 Q2 64,306,768 $1,024,584,616 -$11,033,099 $16.12 95
2024 Q1 63,276,125 $1,352,112,050 +$24,497,831 $21.42 86
2023 Q4 63,746,436 $970,147,653 -$75,831,576 $15.27 69
2023 Q3 67,913,856 $1,531,662,383 +$134,844,672 $21.99 72
2023 Q2 61,447,059 $1,522,893,399 +$1,522,893,346 $23.80 56
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .